These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 16109498)

  • 1. Pathological hypersexuality predominantly linked to adjuvant dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    Klos KJ; Bower JH; Josephs KA; Matsumoto JY; Ahlskog JE
    Parkinsonism Relat Disord; 2005 Sep; 11(6):381-6. PubMed ID: 16109498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine agonist-triggered pathological behaviors: surveillance in the PD clinic reveals high frequencies.
    Hassan A; Bower JH; Kumar N; Matsumoto JY; Fealey RD; Josephs KA; Ahlskog JE
    Parkinsonism Relat Disord; 2011 May; 17(4):260-4. PubMed ID: 21310646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pramipexole, ropinirole, and mania in Parkinson's disease.
    Singh A; Althoff R; Martineau RJ; Jacobson J
    Am J Psychiatry; 2005 Apr; 162(4):814-5. PubMed ID: 15800169
    [No Abstract]   [Full Text] [Related]  

  • 4. Pathological behaviors provoked by dopamine agonist therapy of Parkinson's disease.
    Ahlskog JE
    Physiol Behav; 2011 Jul; 104(1):168-72. PubMed ID: 21557955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Duration of L-dopa and dopamine agonist monotherapy in Parkinson's disease.
    Nissen T; Newman EJ; Grosset KA; Daghem M; Pal G; Stewart M; Odin P; Macphee GJ; Grosset DG
    Scott Med J; 2012 Nov; 57(4):217-20. PubMed ID: 23002158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Dopaminergic agonists in the treatment of Parkinson's disease].
    Supiot F; Sternon J; Zegers de Beyl D
    Rev Med Brux; 2000 Dec; 21(6):493-9. PubMed ID: 11194495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological gambling in Parkinson's disease.
    Stocchi F
    Lancet Neurol; 2005 Oct; 4(10):590-2. PubMed ID: 16168925
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination of two different dopamine agonists in the management of Parkinson's disease.
    Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
    Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Several classes of new drugs emerging for Parkinson disease.
    Phillips P
    JAMA; 1999 Sep; 282(10):929-31. PubMed ID: 10485664
    [No Abstract]   [Full Text] [Related]  

  • 10. The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease.
    Molho ES; Factor SA; Weiner WJ; Sanchez-Ramos JR; Singer C; Shulman L; Brown D; Sheldon C
    J Neural Transm Suppl; 1995; 45():225-30. PubMed ID: 8748629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of sudden onset of sleep in Parkinson's disease.
    Körner Y; Meindorfner C; Möller JC; Stiasny-Kolster K; Haja D; Cassel W; Oertel WH; Krüger HP
    Mov Disord; 2004 Nov; 19(11):1298-305. PubMed ID: 15389999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypersexuality due to dopaminergic drugs.
    Prescrire Int; 2005 Dec; 14(80):224. PubMed ID: 16400746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
    Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
    Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
    Pahwa R
    J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramipexole and ropinirole for Parkinson's disease.
    Med Lett Drugs Ther; 1997 Nov; 39(1014):109-10. PubMed ID: 9398824
    [No Abstract]   [Full Text] [Related]  

  • 18. Unusual compulsive behaviors primarily related to dopamine agonist therapy in Parkinson's disease and multiple system atrophy.
    McKeon A; Josephs KA; Klos KJ; Hecksel K; Bower JH; Michael Bostwick J; Eric Ahlskog J
    Parkinsonism Relat Disord; 2007 Dec; 13(8):516-9. PubMed ID: 17544807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current advances in Parkinson's disease.
    Ball J
    Trends Neurosci; 2001 Jul; 24(7):367-9. PubMed ID: 11467283
    [No Abstract]   [Full Text] [Related]  

  • 20. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson's disease.
    Odiyoor M; Kobylecki C; Hackett RJ; Silverdale MA; Kellett MW
    Mov Disord; 2009 Dec; 24(16):2434-5. PubMed ID: 19891000
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.